Maternal care for anti-D [Rh] antibodies, third trimester (fetus 3)
ICD-10 O36.0133 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, third trimester (fetus 3).
O36.0133 refers to maternal care for a pregnant woman who has developed anti-D (Rh) antibodies during her third trimester, specifically concerning the third fetus. This condition arises when an Rh-negative mother is exposed to Rh-positive fetal blood, leading to the production of antibodies that can cross the placenta and affect the fetus. The presence of these antibodies can lead to complications such as hemolytic disease of the newborn, fetal growth restriction, and fetal distress. Monitoring and management strategies are crucial during this period to assess fetal well-being, including ultrasound evaluations for growth and Doppler studies to assess blood flow. Maternal care may involve additional interventions such as Rh immunoglobulin administration, close surveillance of fetal heart rate patterns, and potential early delivery if fetal distress is noted. The management of anti-D antibodies is essential to prevent severe outcomes for the fetus and ensure a safe delivery.
Detailed documentation of maternal blood type, antibody screening results, and fetal monitoring.
Management of Rh incompatibility in pregnancies, monitoring for fetal distress, and planning for delivery.
Consideration of maternal history and previous pregnancies affected by Rh incompatibility.
Comprehensive documentation of high-risk factors, ultrasound findings, and management plans.
Assessment of fetal growth restriction and planning for potential interventions.
Close collaboration with obstetricians and pediatricians for coordinated care.
Used for monitoring fetal growth in patients with anti-D antibodies.
Document the reason for the ultrasound and findings related to fetal growth.
Obstetricians should ensure that the ultrasound is performed in accordance with guidelines for high-risk pregnancies.
Anti-D antibodies can lead to serious complications for the fetus, including hemolytic disease, which can cause anemia and other health issues. Monitoring and management are essential to ensure fetal well-being.
